Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - February 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, from 23 February 2026, 15:00 (CET) to 23 February 2026, 17:00 (CET)

Human medicines European public assessment report (EPAR): Enurev Breezhaler, glycopyrronium bromide, Date of authorisation: 28/09/2012, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Tovanor Breezhaler, glycopyrronium bromide, Date of authorisation: 28/09/2012, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Seebri Breezhaler, glycopyrronium bromide, Date of authorisation: 28/09/2012, Revision: 14, Status: Authorised

Annex to agenda of the CHMP meeting 26-29 January 2026

Agenda of the CHMP meeting 26-29 January 2026

Human medicines European public assessment report (EPAR): Triumeq, abacavir,dolutegravir,lamivudine, Date of authorisation: 31/08/2014, Revision: 39, Status: Authorised

Human medicines European public assessment report (EPAR): Kisqali, ribociclib, Date of authorisation: 22/08/2017, Revision: 25, Status: Authorised

Human medicines European public assessment report (EPAR): Zegalogue, dasiglucagon, Date of authorisation: 24/07/2024, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Tevimbra, tislelizumab, Date of authorisation: 15/09/2023, Revision: 16, Status: Authorised